🇺🇸 FDA

Intelligence · Patent portfolio

United Therapeutics Europe Patents

Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.

Patents
3,720
Expiring ≤24m
234

Quick answer

United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.

Page 18 of 78

  1. US 10683362

    Recombinant immunotoxin targeting mesothelin

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10683270

    Cannabinoid receptor mediating compounds

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10682393

    Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10683277

    Triazole derivatives as P2Y14 receptor antagonists

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10682379

    Use of gram negative species to treat atopic dermatitis

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10683316

    Synthetic catalase/superoxide dismutase mimetics and methods for treating viral infections

    Expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10676528

    Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10675283

    Compositions and methods for white to beige adipogenesis

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10676475

    Compounds for improving mRNA splicing

    Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10668114

    Use of gram negative species to treat atopic dermatitis

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10668127

    Method and composition for synchronizing time of insemination

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10668087

    Methods for inhibiting muscle atrophy

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10662238

    Single domain VHH antibodies directed to norovirus GI.1 and GII.4 and their use

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10655109

    Recombinant respiratory syncytial virus stains with mutations in the M2-2 ORF providing a range of attenuation phenotypes

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10654898

    Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10653727

    Use of gram negative species to treat atopic dermatitis

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10646591

    Imaging agents for imaging protease activity and uses thereof

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10647754

    Stabilized single human CD4 domains and fusion proteins

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10646588

    RP2 and RPGR vectors for treating X-linked retinitis pigmentosa

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10639320

    Pharmaceutical composition comprising gold-containing agent for preventing or treating liver fibrosis or liver cirrhosis

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10640571

    Human monoclonal antibodies specific for glypican-3 and use thereof

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10640771

    Compositions and methods for treating and preventing macular degeneration

    Expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10633447

    Soluble engineered monomeric Fc

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10632185

    Chimeric west nile/zika viruses and methods of use

    Expires Mon Apr 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10626399

    Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)

    Expires Mon Apr 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10611815

    T cell receptors recognizing MHC class II-restricted MAGE-A3

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10611816

    Anti-KRAS-G12D T cell receptors

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10614684

    Treatment of kidney diseases associated with elevated AVP

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10604582

    Anti-CD276 antibodies (B7H3)

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10604499

    MYC G-quadruplex stabilizing small molecules and their use

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10604548

    Minicircle DNA vector vaccine platform for foot-and-mouth disease and methods thereof

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10603296

    Compositions and methods for diagnosis and treatment of neuromuscular disorders

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10596227

    Polypeptide targeting to mitochondria

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10596185

    Flavonoid compositions and uses thereof

    Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10588984

    Virus-like particle conjugates for diagnosis and treatment of tumors

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10590074

    Potent and selective inhibitors of monoamine transporters; method of making; and use thereof

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10583173

    Methods of treating or preventing pruritis by blocking natriuretic polypeptide b

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10583148

    Methods and devices for bone infection treatment selection

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10584161

    Monoclonal antibodies specific for heartland virus and methods of their use

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10584355

    Chimpanzee adenoviral vector-based filovirus vaccines

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10583159

    Method for increasing performance of offspring

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10577349

    Quinolinones as inhibitors of translation initiation complex

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10577368

    A3 adenosine receptor agonists

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10576059

    Substituted phenylpyrrolecarboxamides with therapeutic activity in HIV

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10576091

    Tomatidine, analogs thereof, compositions comprising same, and uses for same

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10568956

    Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10570214

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10570172

    Self-assembling amphiphilic peptides

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does United Therapeutics Europe have?

3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do United Therapeutics Europe patents expire?

234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.